Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Targeted Therapies Patient Forum September 2017 Speaker Highlight - James Stevenson, MD
dbrock
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum in September 2017.
***Speaker Highlights***
for full faculty bio's, please visit our FACULTY page
Learn about James P. Stevenson, MD, Cleveland Clinic Taussig Cancer Center.
Dr. Stevenson is currently a Staff Physician at the Cleveland Clinic where he serves as Vice-Chairman of the Taussig Cancer Institute Department of Hematology and Oncology. Dr. Stevenson received his B.A. from the University of Notre Dame, Notre Dame, IN. He is a graduate of Jefferson Medical College, Philadelphia, PA and completed his internship in medicine at the University of Florida Hospitals. He then completed his residency in internal medicine followed by a fellowship in hematology and medical oncology at Thomas Jefferson University Hospital, Philadelphia, PA. He is board certified in medical oncology.
His areas of clinical and research interest include the treatment of thoracic malignancies, with a focus on lung cancers and malignant mesothelioma. He leads the Multi-Disciplinary Pleural Mesothelioma Program at the Cleveland Clinic.
Targeted Therapies in Lung Cancer Patient Forum
September 16, 2017
Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center
See below for our growing list of topics and presenters!
Register at cancerGRACE.org | Agenda is subject to change
| 8:30 – 10:00 am | The Many Faces of Progression Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies Dr. Karen Reckamp, City of Hope |
|
| 10:30 – noon |
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West
|
|
|
BREAKOUT SESSIONS |
||
|
1:00 – 2:30 pm
|
Presentations by Lung Cancer Sub-type *Available treatment options *Acquired resistance: How do you pick your next treatment? ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient
|
|
|
BREAKOUT SESSIONS |
||
|
2:50 – 4:00 pm
|
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger
|
|
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, Vernon Sondak, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and Fiorinda Muhaj, MD Anderson Cancer Center, discuss basal and squamous cell carcinoma, including diagnosis, treatment options, and skin cancer prevention.
To watch the complete playlist, click here.
Thanks to Regeneron and Daiichi-Sankyo.
Online Community
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Recent Comments
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: